Vertex Pharmaceuticals (VRTX) – Analysts’ Weekly Ratings Changes

Vertex Pharmaceuticals (NASDAQ: VRTX) recently received a number of ratings updates from brokerages and research firms:

• 1/31/2025 – Vertex Pharmaceuticals had its price target raised by analysts at Scotiabank from $430.00 to $433.00. They now have a “sector perform” rating on the stock.
• 1/31/2025 – Vertex Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.
• 1/31/2025 – Vertex Pharmaceuticals had its “outperform” rating reaffirmed by analysts at William Blair.
• 1/31/2025 – Vertex Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/31/2025 – Vertex Pharmaceuticals had its price target raised by analysts at HC Wainwright from $535.00 to $550.00. They now have a “buy” rating on the stock.
• 1/30/2025 – Vertex Pharmaceuticals was downgraded by analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating. They now have a $460.00 price target on the stock.
• 1/27/2025 – Vertex Pharmaceuticals had its price target lowered by analysts at Piper Sandler from $535.00 to $533.00. They now have an “overweight” rating on the stock.
• 1/24/2025 – Vertex Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $480.00 price target on the stock.
• 1/13/2025 – Vertex Pharmaceuticals had its “outperform” rating reaffirmed by analysts at William Blair.
• 1/10/2025 – Vertex Pharmaceuticals had its price target lowered by analysts at Wells Fargo & Company from $555.00 to $460.00. They now have an “overweight” rating on the stock.
• 12/23/2024 – Vertex Pharmaceuticals had its price target raised by analysts at Scotiabank from $426.00 to $430.00. They now have a “sector perform” rating on the stock.
• 12/23/2024 – Vertex Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $503.00 to $500.00. They now have an “overweight” rating on the stock.
• 12/23/2024 – Vertex Pharmaceuticals had its price target lowered by analysts at Truist Financial Co. from $550.00 to $460.00. They now have a “buy” rating on the stock.
• 12/20/2024 – Vertex Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $566.00 to $520.00. They now have an “outperform” rating on the stock.
• 12/20/2024 – Vertex Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 12/20/2024 – Vertex Pharmaceuticals had its price target lowered by analysts at Barclays PLC from $509.00 to $418.00. They now have an “equal weight” rating on the stock.
• 12/20/2024 – Vertex Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $600.00 to $535.00. They now have a “buy” rating on the stock.
• 12/19/2024 – Vertex Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
• 12/19/2024 – Vertex Pharmaceuticals had its price target lowered by analysts at Bank of America Co. from $545.00 to $522.00. They now have a “buy” rating on the stock.
• 12/16/2024 – Vertex Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $490.00 to $494.00. They now have a “hold” rating on the stock.
• 12/9/2024 – Vertex Pharmaceuticals was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $550.00 price target on the stock, up previously from $500.00.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock traded up $7.45 during mid-day trading on Tuesday, hitting $477.82. 644,950 shares of the stock were exchanged, compared to its average volume of 1,568,617. The firm has a fifty day moving average of $434.73 and a 200 day moving average of $462.62. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a market cap of $123.05 billion, a PE ratio of -240.11, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.67 EPS. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Institutional Trading of Vertex Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in VRTX. Crestwood Advisors Group LLC grew its stake in shares of Vertex Pharmaceuticals by 2.1% in the fourth quarter. Crestwood Advisors Group LLC now owns 5,799 shares of the pharmaceutical company’s stock worth $2,335,000 after acquiring an additional 121 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Vertex Pharmaceuticals by 49.2% during the 4th quarter. IFP Advisors Inc now owns 2,756 shares of the pharmaceutical company’s stock worth $1,114,000 after purchasing an additional 909 shares during the last quarter. HealthInvest Partners AB lifted its position in shares of Vertex Pharmaceuticals by 31.0% during the 4th quarter. HealthInvest Partners AB now owns 22,257 shares of the pharmaceutical company’s stock worth $8,963,000 after purchasing an additional 5,264 shares during the last quarter. Midwest Capital Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth $41,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Vertex Pharmaceuticals in the fourth quarter valued at $2,169,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.